Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

NCT05503953 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

306

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Hypertension

Interventions

DRUG: AGSAVI
DRUG: AGLS

Sponsor

Ahn-Gook Pharmaceuticals Co.,Ltd

Collaborators

[object Object]